Bayer Launches Centafore™ Imaging Core Lab to Support Clinical Trial Imaging and Software as a Medical Device Development

China Finance Network, May 29th: Bayer recently announced the launch of its imaging core laboratory, Centafore.^™。Centafore^™With over 25 years of history, it has supported more than 200 clinical trials for Bayer and its global independent subsidiaries.

This launch means that the brand has become a unique imaging solutions provider, offering customized services to external customers and supporting clinical trials and the development of medical device software across various therapeutic areas and development stages.

Participants in the 2025 American Society of Clinical Oncology Annual Meeting will have the opportunity to learn more about Centafore in Chicago from May 30 to June 3.^™The team, technology, and service.

　　Centafore^™Providing imaging management, processing, and interpretation technologies and services, offering professional project management services to research sponsors, and assisting with advanced analysis of imaging data. Its extensive resource network includes experienced imaging professionals, such as certified radiologists, enabling clients to effectively manage clinical studies across more than 50 countries.

　　“Centafore^™"The launch represents an important step in our commitment to optimizing imaging in clinical trials and advancing the development of new drugs and medical solutions," said Nelson Ambrogio, Global President of Bayer's Imaging Diagnostics business. With extensive experience and expertise, Bayer is committed to providing high-quality imaging services to meet clients' specific needs in clinical research. "Through Centafore..."^™"We aim to enhance the reliability of trial results and support high-quality decision-making during the drug development process, ultimately benefiting patients and improving their healthcare quality."

This service covers multiple therapeutic areas, including oncology, cardiovascular diseases, central nervous system (CNS) disorders, dermatology, women's health, pediatrics, and digital health. It aims to assist pharmaceutical, biotechnology, medical device, and digital health companies in conducting early-stage research through Phase IV clinical trials and medical device software development while adhering to regulatory and data privacy compliance standards.

As part of Bayer's ongoing support for global medical startups, imaging core lab services were showcased at the 2024 European Congress of Radiology (ECR). Centafore^™Has cooperated with OBIO^®Collaborate with institutions such as Luxsonic Technologies to utilize clinical imaging as a key tool for improving decision-making in clinical trials and medical device software development.